Laurus Labs Limited has released the audio recording of its first quarter fiscal year 2027 (Q1 FY27) results conference call, providing stakeholders with direct access to management’s commentary on the recent financial performance. The recording is now available for public listening, ensuring transparency and allowing investors to review the detailed discussion regarding the company’s operational and financial outcomes for the period.

The conference call was hosted on July 24, 2026, in adherence to regulatory requirements. This release follows the company’s initial intimation regarding the call, which was communicated to the exchanges on July 09, 2026. The disclosure is made pursuant to Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandate timely dissemination of material information to listed entities’ shareholders.

Compliance and Regulatory Filing

The announcement was formally submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). The filing was signed by G. Venkateswar Reddy, who serves as the Company Secretary and Compliance Officer for Laurus Labs Limited. The digital signature confirms the document’s authenticity and submission timestamp as July 24, 2026, at 22:51:47 IST.

Accessing the Recording

Investors and analysts can access the full audio recording through the web link provided in the official exchange filing. This resource allows for a comprehensive review of the questions and answers session, offering deeper insights into the drivers behind the reported figures for Q1 FY27. The recording serves as a primary source for understanding management’s perspective on market conditions, competitive positioning, and future outlook.

Corporate Information

Laurus Labs Limited maintains its registered office in Andhra Pradesh, located at Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anapalli District – 531021. The company’s corporate office is situated in Hyderabad, Telangana, at Plot No. 103, Road No 1, Jubilee Hills. Stakeholders may contact the company via telephone at +91 891 682 1101 or +91 40 6659 4333, or through email at info@lauruslabs.com .

Laurus Labs is on track to boost its capital expenditure across a broad range of growth-oriented segments, with investments planned for FY27 and FY28. The company's capex strategy spans both its human health and animal health businesses, alongside emerging high-value areas including peptides, gene therapy, and antibody drug conjugates (ADCs).

Capex Focus Areas

The planned capital expenditure covers a diverse set of therapeutic and technology platforms. The key segments targeted for investment are outlined below:

Strategic Investment Across FY27 And FY28

The capital expenditure initiative underscores Laurus Labs' commitment to expanding its manufacturing and research capabilities across both established and next-generation pharmaceutical segments. By directing investments into peptides, gene therapy, and antibody drug conjugates, the company is positioning itself within some of the fastest-growing areas of the global pharmaceutical and biotechnology landscape. The simultaneous focus on human and animal health segments indicates a broad-based growth approach across its existing business verticals.